Market Insights Health Hospitals Inpatient Care

Neoplasm Treatment - Canada

Canada

Canada's Neoplasm Treatment market is anticipated to witness a significant growth in revenue, with projections indicating that it will reach a staggering US$6.38bn by 2024.
This growth is expected to continue at a steady pace, with an estimated annual growth rate (CAGR 2024-2029) of 4.55%.
As a result, the market volume is predicted to reach US$7.97bn by 2029.
When compared on a global scale, it is noteworthy that United States is anticipated to generate the highest revenue in the Neoplasm Treatment market, with a projected revenue of US$90.56bn in 2024.
Canada is at the forefront of innovative neoplasm treatment research, with leading medical institutions pioneering cutting-edge therapies.

Key regions: Europe, Canada, Brazil, United States, United Kingdom

Market

Region

Region comparison

Currency

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on revenue received by hospitals from public or private sources, allocated to the country where the money is spent, including VAT if applicable.

Modeling approach / Market size:

Market sizes are determined by a bottom-up approach, based on a specific rationale for each market market. Next, we use relevant key market indicators and data from country-specific associations, such as healthcare expenditure per capita, health risk factors, public health spend, and GDP. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level.